Department of Medicine, Indiana Center for Vascular Biology and Medicine, Indiana University School of Medicine, Indianapolis, USA.
AIDS. 2010 Jun 1;24(9):1377-80. doi: 10.1097/QAD.0b013e3283396024.
We performed a single-arm, open-label pilot trial of the anti-inflammatory drug pentoxifylline to reduce systemic inflammation and improve endothelial function, measured by flow-mediated dilation of the brachial artery, in HIV-infected patients not requiring antiretroviral therapy. Pentoxifylline significantly reduced circulating levels of vascular cell adhesion molecule-1 and interferon-gamma-induced protein and significantly improved endothelial function during the 8-week trial. Pentoxifylline may reverse HIV-related endothelial dysfunction by directly inhibiting the endothelial leukocyte adhesion pathway.
我们进行了一项单臂、开放标签的先导试验,研究了抗炎药物己酮可可碱(pentoxifylline)在不需要抗逆转录病毒治疗的 HIV 感染患者中减少全身炎症和改善内皮功能(通过肱动脉血流介导的扩张来衡量)的作用。己酮可可碱在 8 周的试验中显著降低了循环血管细胞黏附分子-1 和干扰素-γ诱导蛋白的水平,并显著改善了内皮功能。己酮可可碱通过直接抑制内皮白细胞黏附途径,可能逆转 HIV 相关的内皮功能障碍。